TBIOTelesis Bio Inc.

Nasdaq codexdna.com


$ 1.67 $ -0.21 (-11.6 %)    

Friday, 13-Sep-2024 12:53:48 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 1.6
$ 1.56
$ 1.60 x 100
$ 1.70 x 100
$ 1.56 - $ 1.70
$ 1.45 - $ 24.48
238,460
na
2.84M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 telesis-bio-q2-adj-762-misses-403-estimate-sales-155m-miss-650m-estimate

Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(7.62) per share which missed the analyst consensus estimate of $(4.03)...

 telesis-bio-shares-resume-trade
Telesis Bio Shares Resume Trade
07/31/2024 15:37:35

 telesis-bio-q1-2024-adj-eps-552-misses-023-estimate-sales-3440m-miss-6900m-estimate

Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(5.52) per share which missed the analyst consensus estimate of $(0.23)...

 telesis-bio-announces-1-for-18-reverse-stock-split-will-open-for-trading-on-the-nasdaq-global-select-market-on-may-9-2024-on-a-post-split-basis

Telesis Bio Inc. (the Company) (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate th...

 telesis-bio-inc-announces-strategic-focus-on-game-changing-gibson-sola-enzymatic-dna-synthesis-platform-and-bioxp-mrna-solutions--todd-r-nelson-to-step-down-as-ceo-eric-esser-president-and-coo-of-telesis-bio-will-assume-the-role-of-the-cos-cep-effective-immediately

Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in str...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION